Serum Institute of India (SII), the company manufacturing Covishield -- the local version of the Oxford–AstraZeneca COVID-19 vaccine, has sought indemnity protection against liabilities, news agency ANI reported quoting sources.from IndiaTV India: Google News Feed https://ift.tt/3vSx5Ss
via
No comments:
Post a Comment
Please do not enter spam link in the comment box. Suggestions are invited for improvement.